Antiretroviral Agents in HIV-1 (trial)

DHHSHIV14033a 106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 For additional copies: info@GuidelineCentral.com Copyright © 2013 All rights reserved Disclaimer is Guideline attempts to define principles of practice that should produce high-quality patient care. It focuses on the needs of primary care practice, but also is applicable to providers at all levels. is Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. e ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. Sources HIV/AIDS News. Recommendation on integrase inhibitor use in antiretroviral treatment-naive HIV- infected individuals from the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. October 30, 2013. Available at http://aidsinfo.nih.gov/news/1392/hhs-panel-on-antiretroviral- guidelines-for-adults-and-adolescents-updates-recommendations-on-insti-based-regimens-for-art-naive- individuals. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Updated February 12, 2013. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Rating Scheme for Recommendations Strength of Recommendation Quality of Evidence for Recommendation A: Strong recommendation for the statement I: One or more randomized trials with clinical outcomes and/or validated laboratory endpoints B: Moderate recommendation for the statement II: One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes C: Optional recommendation III: Expert opinion Abbreviations 3TC, lamivudine; ABC, abacavir; AIDs, acquired immunodeficiency syndrome; APV, amprenavir; ART, antiretroviral therapy; ARV, antiretroviral; ATV, atazanavir; AV, atrioventricular; AZT, zidovudine; bid, twice daily; BMD, bone mineral density; BUN, blood urea nitrogen; CCR5, chemokine receptor 5; CBC, complete blood cell count; CD4, cluster of differentiation 4; CrCl, creatinine clearance; CNS, central nervous system; COBI, cobicistat; CYP, cytochrome P; d4T, stavudine; D bili, direct bilirubin; ddI, didanosine; DHHS, US Department of Health and Human Services; DLV, delavirdine; DRV, darunavir; DTG, dolutegravir; Dx, diagnosis; EC, enteric coated; ECG, electrocardiogram; EFV, efavirenz; eGFR, estimated glomerular filtration rate; EIA, enzyme immunoassay; ETR, etravirine; EVG, elvitegravir; FPV, fosamprenavir; FTC, emtricitabine; GI, gastrointestinal; HBV, hepatitis B virus; HIV, human immunodeficiency virus; HLA-B, human histocompatibility surface antigen encoded by the b locus; HSR, hypersensitivity reaction; IDV, indinavir; IGRA, interferon-gamma release assay; INSTI, integrase strand transfer inhibitor; LPV, lopinavir; MDR, multidrug resistant; MI, myocardial infarction; MVC, maraviroc; NFV, nelfinavir; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; Pap, stained cells in a cervical smear; PI, protease inhibitor; PPI, proton pump inhibitor; pts, patients; q, every; /r, low-dose ritonavir; RAL, raltegravir; RNA, ribonucleic acid; RPR, rapid plasma reagin; RPV, rilpivirine; RTV, ritonavir; SJS, Stevens-Johnson syndrome; SQV, saquinavir; STDs, sexually transmitted diseases; T-20, enfuvirtide; TAM, thymidine analogue mutation; TB, tuberculosis; T bili, total bilirubin; TDF, tenofovir disoproxil fumarate; TEN, toxic epidermal necrosis; tid, three times daily; TPV, tipranavir; TST, tuberculin skin test; VDRL, Venereal Disease Research Laboratory slide test; XDR, extensively drug resistant; ZDV, zidovudine.

• Cover